So far, a TRAIL conjugate with monomethyl auristatin E (MMAE), the TRAIL-MMAE, was shown to deliver a potent antitumor response in breast carcinoma xenograft animal models (Pan et al., 2015). The gene discussed is TNFSF10; the disease is breast carcinoma.